complex. 1, 2 This distinction has made this pathway a promising target for antimicrobial drug design. 3, 4 The FAS II pathway is composed of 4 enzymes in an iterative process of fatty acid elongation, in which the enoyl acyl-carrier protein reductase (ENR) has gained the most attention with a range of drugs developed against it. These include the anti-tuberculosis drug isoniazid, the diazaborine family and triclosan which is a common antimicrobial found in, amongst other things, toothpastes, mouthwashes and chopping boards. 5, 6, 7, 8 Triclosan has been shown to be a very potent inhibitor which binds at the core of the ENR enzyme, making stacking interactions with the reduced NAD + cofactor. 9 Its binding mode has been characterised as a two state process, where it primarily interacts with the NAD + cofactor followed by an -helix packing over the triclosan, burying it away from the solvent forming a slow tight binding complex. 10 Triclosan is a relatively simple scaffold which has been extensively modified by a number of groups to improve its ADMET properties.
Significant progress has been made toward the development of both T. gondii and P. falciparum medicines through the discovery of a FAS II pathway residing within their apicoplast. 11, 12 This was particularly pertinent when it was discovered that the P. falciparum, E. tenella and T. gondii ENR enzyme could be inhibited by the potent antibacterial triclosan. 13, 14, 15 Since this discovery, a number of groups have developed a range of triclosan analogues which have shown potent inhibitory effects often with improved ADMET properties. [16] [17] [18] [19] [20] [21] Although studies have reported that FASII is not essential for blood stage survival of P. falciparum it does play an important role in liverstage development. Moreover, triclosan may have an off target effect within the blood stage of its lifecycle. 22, 23 A significant problem with these inhibitors is the need to cross several membranes imposed by the host cell, parasite and apicoplast in order to reach the ENR enzyme target. This has been aided with some success through the addition of a cleavable linker and transductive peptide, although further work in this area is needed. 24 In order to establish if a more stable, non releasable molecular transporter can be attached to the A-or B-ring of triclosan in a way that does not significantly alter binding to ENR, we have taken two of our previously successful triclosan modifications which resulted in extensions on the A-and B-ring and combined them. In particular, isoxazole groups were chosen since they retained good potency whilst improving the physiochemical properties (Stec et al., in press). This has resulted in a set of three compounds with potent inhibitory effects and isoxazole extensions, which allow through the incorporation of functional groups to be further utilised for the addition of a linker and transductive peptide or a non-releaseable linker.
The compounds were generated by reacting 4-Hydroxy-3-methoxybenzonitrile with 3-chloro-4-fluorobenzaldehyde to give intermediate 1, which was readily converted to the imidoly chloride 3 in a two-step protocol. 25 Subsequent reaction of 3 with TBDPS protected 3-butyn-1-ol and 1-pentyne afforded the corresponding isoxazoles 4 and 5. 26 The final compounds, 6 and 7, were prepared by the modified demethylation procedure 27 with BBr 3 , employing 4 and 5 as the starting materials.
Reduction of the nitrile 5 provided amine intermediate 8, which was further elaborated through amide bond formation with 5-methylisoxazole-3-carboxylic acid and demethylation to give the final product 10. 28 Full details on compound synthesis are in the supplemental material.
Inhibitory assays for parasite replication, toxicity against fibroblast host cell tests methods, and enzyme assays were performed as previously described (Stec et al., in press). 21, [29] [30] [31] [32] A major hurdle in targeting pathways which reside within the apicoplast is the need for the inhibitor to cross several membrane barriers. In order to avoid this difficulty, we adapted the triclosan scaffold to contain bulky substituents on both the A-and B-rings that were amenable to the addition of non-releasable transport peptides (( Table 1 ) ( Figure 1A) ). The relatively small binding pocket means that these non-releasable linkers must sit outside the cavity, exposed to the solvent to avoid any steric hindrance upon inhibitor binding.
In the first instance, we used a previously identified modification on the triclosan B-ring whereby a substituted-isoxazole group was added at the 4 -position. 32 This group makes favourable interactions around the entrance of the triclosan binding site and extends out towards the solvent.
In order to test whether further modifications could be placed at the exit of the binding site, the substituent on the isoxazole ring was replaced with either a 5-propyl or 5-ethyl alcohol group. Although only a minimal improvement in the MIC 50 ; from 10 M to 4 M (6) and 7.5 M (7) is seen, no detrimental effect to the enzymatic activity is observed. Importantly, docking studies have shown that both of these extensions can clearly protrude from the hydrophobic binding site towards a more solvent exposed area of the enzyme ( Figure 1B) . Further structural modification of the isoxazole ring could allow for conjugation to a delivery peptide via either a releasable or non-releasable linker.
A more challenging aspect of the project was to produce a modification on the A-ring of triclosan, which occupies an enclosed hydrophobic region, resulting in its exposure to the outside solvent thus allowing for its attachment to a delivery peptide. This is due to the Aring of triclosan being buried within the binding site, whereas the B-ring is at the base of a channel which leads to the solvent. The tight packing about the A-ring within the ENR enzyme binding site often makes modifications about this ring difficult as there are several residues predicted to make steric clashes with these modified structures, as seen in docking simulations. It is important to note however that most modeling programs do not account for protein flexibility within the binding site. 33 A solution to this problem was suggested through previous studies of compound 33 ( Figure  2(Stec et al., in press) ). This compound was predicted to bind in a reverse mode to that of triclosan, i.e. the A-ring would take the position of the B-ring and vice versa, by the FlexX docking program. This altered pose was observed due to the large substituent on the A-ring causing severe steric clashes within the binding site which could only be relieved through the reverse binding mode. However, by allowing for flexibility within the active site, in particular the movement of Phe243 about C within the TgENR/NAD + complex using the Swiss PDB Viewer the original binding mode was seen. 34 Those orientations that could accommodate the greater steric bulk of our hybrid compounds resulted in a more open binding site such that the A-ring modification is now exposed to the exterior solvent ( Figure  1C, D) . We have previously seen the movement of Phe243 about the C , in a manner similar to that of the modeling in a TgENR co-crystal structure for a different family of inhibitors (data not shown). Subsequent docking of the compound series was carried out using AutoDock 4.2 35 or Macromodel version 8.1 36 and PDB IDs 2O2S 20 and 1LX6 37 available from the RCSB Protein DataBank. A hybrid triclosan scaffold was then designed which contained both A and B ring modifications allowing for the compound to be exposed to the solvent on both ends of the molecular scaffold (10) . Modeling studies for this compound with increased bulk on both the A-and B-rings does not permit the reverse mode binding seen for the compound 33, but instead adopts the position shown in Figure 1 . Importantly, this compound, despite its bulkier nature, showed no decrease in MIC 50 value but a slight increase in IC 50 value from 29 nM (6) and 19 nM (compound 33) to 137 nM (10) . This increase in IC 50 to 137 nM is still therapeutically viable and more importantly, the modifications to both the A and B-ring has resulted in a compound which is amenable to further structural modifications to improve both binding and delivery via releasable/non-releasable trans-peptide linkers. In vitro cytotoxicity tests also showed no noticeable increase in toxicity based on the assay used. Growth was measured using a type 1 T. gondii parasite tachyzoite RH stably transfected with the yellow fluorescent protein (RH-YFP) gene, with the relative fluorescence intensities of the parasites being directly correlated with parasite viability and numbers (Figure 3) .
The activity of the 3 compounds (6, 7 & 10) were also tested against two different strains of P. falciparum (D6 & TM91C235) in a dose-response growth inhibition assay. Only 6 showed modest activity against the drug sensitive strain, D6, but no activity against the drug resistant strain, TM91C235 (Table 1 ). It is likely that the non-essential nature of the FASII pathway within the blood stage of the P. falciparum is responsible for the poor inhibitory effect of these compounds within our assay. 22 Further work will determine the potency of these inhibitors against the liver stage parasite which would be important in stopping recrudescence of the Plasmodium parasite.
These results have shown how the triclosan scaffold can be modified to result in both the Aand B-rings being exposed to the exterior solvent without a significant loss in potency or detectable increase in toxicity. This is important since it allows for further structural modifications to be made which are not constrained by the size of the binding site. This also allows for the addition of chemical functionalities which may aid in the delivery of triclosan into the apicoplast, a significant problem in current drug design. Moreover, the bradyzoite form of T. gondii is currently impossible to treat with current therapeutics due to the barriers put in place by the cyst form of the parasite. Further work will be carried out to use this scaffold as a basis for modifications by various linker elements which may aid in drug delivery and targeting of a compound whose potency is in the nanomolar range.
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